Company news
Oncology Pharma Inc. (OTC:ONPH) news
Oncology Pharma Inc. news releases on 6ix. Latest, May 7, 2026: Natera Reports First Quarter 2026 Financial Results
Press releases & updates
Natera Reports First Quarter 2026 Financial Results
May 7, 2026
Tempus Reports Fourth Quarter and Full Year 2025 Results
February 24, 2026
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
February 3, 2026
McKesson Corporation Completes Divestiture of Norwegian Operations
January 30, 2026
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
July 11, 2022
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
June 28, 2022
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
June 7, 2022
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 8, 2022
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 12, 2022
Oncology Pharma Reports on Progress with Ribera Solutions
March 1, 2022
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
February 22, 2022
Oncology Pharma Expands on Feasibility Studies and Data
February 16, 2022
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
February 13, 2022
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
February 7, 2022
Oncology Pharma's New Year Update
January 9, 2022
Oncology Pharma Meeting Towards Future Developments
December 16, 2021
Oncology Pharma Year End Review and Outlook
December 8, 2021
Oncology Pharma Research and Vision
November 29, 2021
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 7, 2021
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 26, 2021
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 14, 2021
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 11, 2021
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 12, 2021
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 22, 2021
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 18, 2021
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 19, 2021
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 29, 2021
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 14, 2021
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
June 8, 2021
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
May 17, 2021
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
May 11, 2021
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
May 6, 2021
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
April 20, 2021
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
April 13, 2021
Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer
April 6, 2021
Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
March 31, 2021
Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
March 16, 2021
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy
March 10, 2021
Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies
March 4, 2021
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
February 26, 2021
Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology
February 22, 2021
Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board
February 16, 2021
Oncology Pharma Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform
February 9, 2021
Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology
February 3, 2021
Oncology Pharma Announces the Appointment Of New Chief Financial Officer
January 28, 2021
Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split
August 27, 2020
Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches
April 20, 2020
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19
April 6, 2020
Oncology Pharma, Inc. Narrows Focus on Funding Efforts
January 28, 2020
CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd
December 25, 2019